The Xinxin Pharmaceutical Factory, a branch of Darentang under Tianjin Pharmaceutical Darentang Group Corporation, has recently obtained the drug registration certificate for Saxagliptin and Metformin Hydrochloride Extended-Release Tablets (I) approved and issued by the National Medical Products Administration. The product specification is each tablet containing saxagliptin 5 mg and metformin hydrochloride 1,000 mg, registered as a Category 4 chemical drug, and deemed to have passed the consistency evaluation. This drug, used in combination with diet and exercise, is indicated for adult patients with type 2 diabetes and was co-developed by Bristol-Myers Squibb and AstraZeneca.
Tianjin Zhongxin Pharmaceutical Group Corp LtdDarentang, a branch of Tianjin Zhongxin Pharmaceutical, received a drug registration certificate for a new diabetes drug, indicating product approval and market entry.
